Cancer Drug Supplier’s IPO Mints China’s Latest Billionaire

January 6, 2023

Today’s listing at the Shanghai Stock Exchange by Sichuan Biokin Pharmaceutical, a supplier of cancer drugs, has minted China’s latest billionaire.

Chairman Zhu Yi directly owns 298.1 million shares, worth 10 billion yuan, or $1.5 billion in early afternoon trading. Shares rose 36% from their IPO price to 33.69 yuan.

Zhu holds an undergraduate degree in radio technology, as well as a master’s degree in biology from Fudan University and a doctorate in management from Sichuan University. He taught immunology and microbiology at West China Medical University in 1987-1990.

Zhu founded Biokin in 1996. It operates in the U.S. through a Redmond, Washington-based subsidiary, Systimmune. China securities regulators approved Biokin’s IPO in December.

The country and the U.S. rank No. 1 and No. 2 in the number of cancer patients and overall cancer burden. China is home to the world’s second-largest number of billionaires after the United States.

— with Julie Lu

See related posts:

U.S., China Advance Discussions To Accelerate Cancer Drug Trials

China’s Richest See Record Plunge In Wealth

New Questions Arise For U.S. Businesses In China After “Jarring” End To Zero-Covid Policy


Source link

Score LA is a website dedicated to the sprawling California city in the south, which happens to be the heart of the United State's movie and TV industry. Near the iconic Hollywood sign stands the studios Paramount Pictures, Universal, and Warner Brothers, along with others that also give behind-the-scenes tours.
Additional Information
Copyright © 2023 Score LA. All Rights Reserved. Protection Status